Why are erythrocyte stimulating agents indicated for patients with end stage renal disease?

Erythropoiesis-stimulating agents (ESAs) act to replace endogenous erythropoietin for patients with end-stage renal disease having anemia. Today, ESAs remain the main tool for treating anemia associated with CKD.

When are erythropoiesis-stimulating agents used?

ESAs are usually given to patients who have chronic (long-lasting) kidney disease or end-stage renal (kidney) disease. These patients usually have lower hemoglobin levels because they can’t produce enough erythropoietin. ESAs are also prescribed for patients who have cancer.

Why are erythropoiesis-stimulating agents ESAs prescribed for patients with chronic kidney disease?

Use of ESAs in the management of anemia of CKD is associated with improved quality of life, increased survival, and decreased progression of renal failure. Some evidence suggests that ESAs have a cardioprotective effect.

How does CKD affect erythropoiesis?

The diminished erythropoiesis in the anemia of chronic renal disease has been attributed to three possible factors: (1) decreased erythropoietin production, (2) inhibition of erythropoietin activity, and (3) decreased bone marrow response to erythropoietin.

What drugs are erythropoiesis-stimulating agents?

The four currently available erythropoiesis-stimulating agents (ESAs), the main drugs for correcting anemia in patients with chronic kidney disease (CKD), are epoetin alfa, epoetin beta, darbepoetin alfa, and continuous erythropoietin receptor activator.

What is ESA in chronic kidney disease?

Erythropoiesis-stimulating agents (ESAs) are commonly used to treat anemia associated with chronic kidney disease (CKD).

How are erythropoiesis stimulating agents used in CKD?

The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach Erythropoiesis-stimulating agents (ESAs) have been used to manage anemia in chronic kidney disease (CKD) to reduce transfusion requirements and anemia symptoms.

Is it safe to take erythropoiesis stimulating agents?

[6-24-2011] The U.S. Food and Drug Administration (FDA) is informing healthcare professionals of modified recommendations for more conservative dosing of Erythropoiesis-Stimulating Agents (ESAs) in patients with chronic kidney disease (CKD) to improve the safe use of these drugs.

Who is deficient in erythropoietin in advanced kidney disease?

It is deficient in the majority of patients with advanced kidney disease thereby predisposing to anemia.

What are the different types of Erythropoietin Stimulating Agents?

Types of erythropoietin stimulating agents (ESA) used in treating anemia in CKD The first recombinant human erythropoietin (EpogenĀ®[epoetin alfa], Amgen) in 1989 (Eschbach et al 1989) significantly improved the clinical management of anemia of CKD, primarily in dialysis patients.